Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
- Conditions
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 198
- Registration Number
- NCT05657158
- Locations
- 🇨🇭
Novartis Investigative center, Basel, Switzerland
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT05653349
- Locations
- 🇺🇸
Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT05653219
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Compassionate Care Res Group Inc, Fountain Valley, California, United States
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT05650060
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 90
- Registration Number
- NCT05648968
- Locations
- 🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 502
- Registration Number
- NCT05646381
- Locations
- 🇺🇸
Minneapolis Heart Institute, Minneapolis, Minnesota, United States
🇺🇸Valley Clinical Trials, Northridge, California, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 406
- Registration Number
- NCT05639114
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
🇺🇸Sahni Rheumatology and Therapy, West Long Branch, New Jersey, United States
🇺🇸NYU Langone Health, Brooklyn, New York, United States
Kesimpta (Ofatumumab) Pregnancy Registry
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 725
- Registration Number
- NCT05634967
- Locations
- 🇺🇸
Novartis Investigative Site, La Jolla, California, United States
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05631795
- Locations
- 🇮🇳
Novartis Investigative Site, New Delhi, India
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT05630001
- Locations
- 🇺🇸
City Of Hope National Med Center, Duarte, California, United States
🇺🇸Lakes Research, Miami Lakes, Florida, United States
🇺🇸Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah, United States